BPC-157 Capsules: Oral BPC-157, the HHS Policy and What Is Known About Absorption

A BPC-157 capsule from a supplement store is not an approved drug and not a compounded drug. Since October 28, 2026, the only oral BPC-157 the federal government has made room for is one compounded by a state-licensed 503A pharmacy on a prescription for a named patient.^[1] Even then, HHS expects the pharmacy to keep documentation that its specific formulation is adequately absorbed by mouth in humans.^[1] No such human data has been published. FDA’s reviewers found no human pharmacokinetic data for BPC-157 taken orally,^[2] and the case for swallowing it rests on test-tube stability in gastric juice and on rat studies.^[3]

Three different products are sold as “BPC-157 capsules”

The same words cover products with very different legal footing. A capsule in a supplement store or on a supplement marketplace is sold as a dietary supplement. FDA’s own briefing for its July 2026 advisory committee notes that BPC-157 is marketed in the United States in dietary supplement capsules and tablets, and that no official USP standard exists for it as a supplement ingredient.^[2] A second kind is sold by research-chemical sites as powder or capsules “not for human consumption.” The third, which only became possible under the HHS policy, is an oral capsule made by a 503A compounding pharmacy for one patient on a prescription.^[1]

The rest of this page explains why the third column carries a condition the other two never face, and why that condition is hard to meet. For how research-chemical sellers differ from pharmacies more broadly, see research-use-only vs compounded peptides.

What the HHS policy requires of oral BPC-157

Appendix B of the policy lists the routes for each of the six covered peptides. For BPC-157 acetate it allows “subcutaneous, intramuscular, oral, and topical dosage forms.”^[1] BPC-157 is one of only two peptides on the list cleared for use by mouth; KPV is the other (see KPV oral and topical). The full set of conditions is explained in the HHS peptide compounding policy.

“Achieving adequate oral bioavailability of peptides is inherently difficult and complex. Therefore, if a peptide is compounded in an oral dosage form, the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans.”^[1]

— HHS enforcement discretion policy, condition 8

Three parts of that sentence matter. The evidence has to concern the specific formulation the patient receives, so a study of some other capsule does not carry over. It has to show absorption in humans, so rat data does not count. And it has to show an adequate level, which the policy does not define. The policy’s testing appendix repeats the point from the other side. It says injection should be the standard route for peptides “due to their low oral bioavailability,” and that any other dosage form needs quality tests specific to that form reported on the certificate of analysis.^[1] For a capsule, FDA’s reviewers named dissolution and microbial quality as the critical attributes.^[2]

The other conditions apply too. The capsule may contain BPC-157 and nothing else, its ingredient must come from an FDA-registered facility with a lot-specific certificate of analysis, the label must carry the compounded-drug statement, and the pharmacy must report serious adverse events to FDA’s MedWatch program.^[1] A capsule that blends BPC-157 with another peptide or with a supplement ingredient falls outside the policy. How to read a peptide certificate of analysis covers what a valid one shows.

Why most peptides are poorly absorbed when swallowed

Peptides are short chains of amino acids, the same material the gut is built to digest. Protein and peptide drugs have almost always needed injection for that reason.^[7] A swallowed peptide has to get past four obstacles in turn: acid and pepsin in the stomach, protein-cutting enzymes in the small intestine, a gut lining that lets few molecules of that size through, and the liver, which processes what is absorbed before it reaches the rest of the body.^[3] Drug makers that have succeeded used permeation enhancers, enzyme inhibitors or chemical changes to the molecule.^[7]

Oral semaglutide shows how small the yield can be even with that engineering. Novo builds an absorption enhancer called SNAC into the tablet, and the label puts its absolute bioavailability at 0.4% to 1% for the three Rybelsus strengths.^[8] It has to be taken with the stomach empty and 4 ounces of water at most, and then nothing to eat or drink for at least 30 minutes.^[8] That tablet was engineered and tested for oral use. A supplement capsule of BPC-157 has had none of that work.

What is known about BPC-157 in the stomach

BPC-157 does have one unusual property. It was derived from a protein in human gastric juice, and the Zagreb group that developed it describes it as “stable in human gastric juice (for more than 24 h).”^[4] FDA’s briefing document accepts that it was reported to resist breakdown in gastric juice in the laboratory, and attributes its short life in the body to enzymes in blood and tissue.^[2] Most peptides are destroyed quickly in stomach acid and pepsin, so this is the property most often cited to justify taking BPC-157 by mouth.^[3]

Surviving the stomach is only the first of the four obstacles. A 2026 review of BPC-157 from a drug-development standpoint put it directly: “gastric stability, while necessary, is not sufficient to establish oral bioavailability.”^[3] The authors found that the remaining three steps have never been measured.

The review tentatively places BPC-157 among high-solubility, low-permeability compounds, the class that dissolves easily but crosses the gut wall poorly, and says that label is provisional until real permeability tests are run.^[3] It also notes that no pharmaceutical-grade formulation of BPC-157 has been developed or validated.^[3]

Oral BPC-157 in animals: effects, but no absorption numbers

Many of the rat studies from the developer group gave BPC-157 by mouth, often dissolved in drinking water. In one, rats with a surgically created fistula between the colon and bladder healed when BPC-157 was given in drinking water or by injection into the abdomen.^[6] Results like that are why sellers say oral BPC-157 works.

They do not show that the peptide reached the bloodstream. Effects in the gut after oral dosing could come from the peptide acting on the gut lining where it lands, without being absorbed at all.^[3] The review’s authors call this local-versus-systemic question the biggest ambiguity in the oral literature, and say the studies do not consistently separate the two.^[3] That distinction matters for anyone taking a capsule for a knee or a tendon.

The one formal animal pharmacokinetic study, in rats and beagle dogs, gave BPC-157 by vein and by intramuscular injection only. It found a half-life under 30 minutes, rapid breakdown into small fragments, and intramuscular bioavailability of about 14% to 19% in rats and 45% to 51% in dogs.^[5] It had no oral arm. FDA’s reviewers noted that the absolute bioavailability of BPC-157 given by mouth to rats or dogs is unknown.^[2]

What is known in people

Less again. FDA’s reviewers wrote that they “found no human pharmacokinetic data for BPC-157 after oral, SC, nasal, or transdermal administration.”^[2] The closest data come from enema studies in the early 2000s, in which BPC-157 was not detected in blood samples; FDA concluded it did not appear to be absorbed systemically that way.^[2]

Two oral studies have been registered. A 2015 phase 1 trial of a BPC-157 tablet in healthy volunteers in Mexico was set up to measure safety and pharmacokinetics.^[9] Its registry entry has not been updated since December 2015 and lists its status as unknown, and FDA could find no results or publication.^[2] A US trial of gummies containing BPC-157, run as a dietary supplement study, is listed as completed with no results posted.^[10] Neither has put a number on oral absorption.

What a supplement-store BPC-157 capsule is

Supplements are regulated as a category of food. Under the 1994 law that created that framework, FDA “does not have the authority to approve dietary supplements before they are marketed,” and a firm generally does not have to show FDA its safety evidence.^[11] Nobody checks a supplement-store BPC-157 capsule for identity, dose or absorption before it goes on sale. For how supplement claims hold up in a related market, see GLP-1 supplements: do they work?

Whether BPC-157 can be a supplement ingredient at all is doubtful. The Defense Department’s Operation Supplement Safety program states that “BPC-157 is not a dietary ingredient. It is an unapproved drug.”^[12] It lists BPC-157 on the DoD Prohibited Dietary Supplement Ingredients List and notes that the World Anti-Doping Agency bans it under class S0, non-approved substances.^[12] Athletes subject to drug testing should treat a BPC-157 supplement as a banned product.

FDA has acted against BPC-157 products sold with disease claims. In 2020, FDA and the Federal Trade Commission warned a seller whose product was labeled to contain BPC-157 and promoted against COVID-19, calling it among a group of “unapproved new drugs.”^[13] For FDA’s record on BPC-157 in compounding, see BPC-157: what FDA actually said.

The HHS policy does not change any of this. It covers only 503A pharmacies and physicians compounding on a patient-specific prescription.^[1] A supplement capsule bought without a prescription, made without the required certificate of analysis and labeled with a Supplement Facts panel meets none of the policy’s conditions. FDA has also flagged that, while oral BPC-157 probably carries a low risk of immune reactions, it remains concerned about impurities in peptide products.^[2] That concern applies most to products nobody tests.

If you want to compare where BPC-157 is sold and how each seller supplies it, see the BPC-157 guide and the BPC-157 provider list. For known adverse effects, see BPC-157 side effects.